Tobacco Use DisorderPhase 2RDECNCT06614504
Nicotine Regulation for Dual Users of E-cigarettes and Cigarettes
A Phase 2 study testing Varying the nicotine content of cigarettes and Varying the nicotine content of e-cigarettes in people with Tobacco Use Disorder, run by University of Vermont at 2 sites in United States.
Trial summary
Cigarette smoking remains the leading cause of preventable morbidity and mortality in the US. Use of multiple tobacco products is becoming increasingly prevalent, with dual use of e-cigarettes and cigarettes representing the most common combination. Read more about this study
- Who is it for?
- Ages 21 years and olderHealthy volunteers can take part
- Conditions the study is for
- Tobacco Use Disorder
- What is being tested?
- Varying the nicotine content of cigarettes and Varying the nicotine content of e-cigarettes
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 308 participants
- Where
- 2 sitesUnited States
- Study dates
- 1 Nov 2024to 30 Sep 2028
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Regular use of tobacco
- 21 year of age or older
- Speak, comprehend and read English well enough to complete study procedures
Who cannot join
- Pregnant, trying to become pregnant, or nursing
- Under the age of 21
- Health conditions that could undermine ability to complete the study
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
United States2 sites, 2 recruiting
- Recruiting
University of Vermont
Burlington, Vermont, 05405
Emily Booth, (802) 213-8956, emily.booth@med.uvm.edu
Shirley Plucinski, shirley.plucinski@uvm.edu
- Recruiting
Brown University
Providence, Rhode Island, 02903
Kim Duguay, 401-863-2988, Kimberly_duguay@brown.edu
Jennifer Tidey, PhD
About this study
Official title: A Randomized Controlled Trial of Reduced Nicotine Cigarettes and E-cigarettes Among Dual Users
Cigarette smoking remains the leading cause of preventable morbidity and mortality in the US. Use of multiple tobacco products is becoming increasingly prevalent, with dual use of e-cigarettes and cigarettes representing the most common combination. Though e-cigarettes are not without risk, completely switching from cigarettes to e-cigarettes likely reduces risk for tobacco-related harm. However, many established dual users maintain long-term smoking and the majority who use e-cigarettes non-daily are at an even greater risk for prolonged smoking than exclusive cigarette smokers. The Food and Drug Administration Center for Tobacco Products (FDA CTP) has announced plans to implement a nicotine-limiting product standard, capping the nicotine in cigarettes at a minimally or non-addictive level. Randomized controlled trials (RCTs) demonstrate that adults who exclusively smoke cigarettes respond to very low nicotine content (VLNC) cigarettes with reductions in smoking, demand, and dependence. However, nicotine reduction RCTs to date have excluded people who regularly use e-cigarettes and therefore it remains unclear how a nicotine-limiting standard for cigarettes would affect smoking among dual users. Given the potential substitutability of e-cigarettes for cigarettes, reducing the nicotine in cigarettes could promote a transition to exclusive e-cigarette use among dual users unable to completely quit nicotine, but only if sufficiently appealing e-cigarettes remain available. E-cigarettes containing 5% nicotine-salt solution are currently most popular in the US, but policy makers have proposed restricting e-cigarettes to ≤ 2% nicotine to curb youth e-cigarette use, and several states have already set limits to reduce nicotine in e-cigarettes. Prior laboratory studies indicate that higher vs lower nicotine e-cigarettes serve as better substitutes for cigarettes among adult dual users. As such, a restriction on e-cigarette nicotine concentration could undermine the potential for e-cigarettes to substitute for cigarettes and diminish the benefits of a nicotine-limiting standard for cigarettes among dual users. This study is a 12-week double-blind 2 cigarette level (Normal Nicotine vs Very Low Nicotine) x 2 e-cigarette level (High Nicotine vs Low Nicotine) between-subjects factorial trial to investigate how a nicotine-limiting standard for cigarettes affects adult dual users and whether these effects are impacted by constraints on e-cigarette nicotine concentration. Outcome measures include cigarettes per day, cigarette dependence, and toxicant exposure. The research is highly relevant to FDA CTP domains of Addiction and Behavior because it will test whether reducing the nicotine content of cigarettes reduces smoking and dependence, and whether these effects are moderated by the availability of high vs low nicotine e-cigarettes.
- Conditions
- Tobacco Use Disorder
- Being tested
- Varying the nicotine content of cigarettes, Varying the nicotine content of e-cigarettes
- Keywords
- Cigarettes, E-cigarettes
- Medical subject headings
- Tobacco Use Disorder, Vaping
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Varying the nicotine content of cigarettesOther
Also called Comparing normal nicotine content (RC 1) to very low nicotine content (RC 2)
Altering the nicotine content of the tobacco research cigarettes
Varying the nicotine content of e-cigarettesOther
Also called Comparing high nicotine content (REC 1) to low nicotine content (REC 2)
Altering the nicotine content of the research e-cigarettes
| Study group | Role | What they receive |
|---|---|---|
| RC 1 + REC 1 | Experimental | Research cigarettes #1 plus research e-cigarettes #1 Receives: Other: Varying the nicotine content of cigarettes; Other: Varying the nicotine content of e-cigarettes |
| RC 1 + REC 2 | Experimental | Research cigarettes #1 plus research e-cigarettes #2 Receives: Other: Varying the nicotine content of cigarettes; Other: Varying the nicotine content of e-cigarettes |
| RC 2 + REC 1 | Experimental | Research cigarettes #2 plus research cigarettes #1 Receives: Other: Varying the nicotine content of cigarettes; Other: Varying the nicotine content of e-cigarettes |
| RC 2 + REC 2 | Experimental | Research cigarettes #2 + research e-cigarettes #2 Receives: Other: Varying the nicotine content of cigarettes; Other: Varying the nicotine content of e-cigarettes |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of cigarettes smoked per day
Measured: 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Sep 2024
- Study start1 Nov 2024
- Primary completion31 Aug 2028 (estimated)
- Study completion30 Sep 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Tobacco Use DisorderStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Factorial
- Model description
- 2x2 factorial randomized controlled trial
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 308 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Vermont
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Elias Klemperer, University of Vermont
- Investigators
- Elias Klemperer, PhD, Principal investigator, University of Vermont
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06614504
- Sponsor's protocol ID
- R01DA059562
- Acronym
- RDEC
- Status last verified
- Sep 2024
- First submitted
- 23 Sep 2024
- Last updated
- 27 Jun 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Data will be made available once we have published the results of the parent trials and manuscripts based on secondary analyses of those data, which we anticipate taking approximately three years.
Study at a glance
From the registry record, last updated by the sponsor on 27 Jun 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized Controlled Trial of Reduced Nicotine Cigarettes and E-cigarettes Among Dual Users
- ClinicalTrials.gov ID
- NCT06614504
- Acronym / sponsor ID
- RDEC / R01DA059562
- Conditions
- Tobacco Use Disorder
- Keywords
- Cigarettes, E-cigarettes
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 308 participants (estimated)
- Lead sponsor
- University of VermontUniversity, hospital or other
- Study start
- 1 Nov 2024 (actual)
- Primary completion
- 31 Aug 2028 (estimated)
- Study completion
- 30 Sep 2028 (estimated)
- First posted
- 26 Sep 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Cigarette smoking remains the leading cause of preventable morbidity and mortality in the US. Use of multiple tobacco products is becoming increasingly prevalent, with dual use of e-cigarettes and cigarettes representing the most common combination. Though e-cigarettes are not without risk, completely switching from cigarettes to e-cigarettes likely reduces risk for tobacco-related harm. However, many established dual users maintain long-term smoking and the majority who use e-cigarettes non-daily are at an even greater risk for prolonged smoking than exclusive cigarette smokers. The Food and Drug Administration Center for Tobacco Products (FDA CTP) has announced plans to implement a nicotine-limiting product standard, capping the nicotine in cigarettes at a minimally or non-addictive level. Randomized controlled trials (RCTs) demonstrate that adults who exclusively smoke cigarettes respond to very low nicotine content (VLNC) cigarettes with reductions in smoking, demand, and dependence. However, nicotine reduction RCTs to date have excluded people who regularly use e-cigarettes and therefore it remains unclear how a nicotine-limiting standard for cigarettes would affect smoking among dual users. Given the potential substitutability of e-cigarettes for cigarettes, reducing the nicotine in cigarettes could promote a transition to exclusive e-cigarette use among dual users unable to completely quit nicotine, but only if sufficiently appealing e-cigarettes remain available. E-cigarettes containing 5% nicotine-salt solution are currently most popular in the US, but policy makers have proposed restricting e-cigarettes to ≤ 2% nicotine to curb youth e-cigarette use, and several states have already set limits to reduce nicotine in e-cigarettes. Prior laboratory studies indicate that higher vs lower nicotine e-cigarettes serve as better substitutes for cigarettes among adult dual users. As such, a restriction on e-cigarette nicotine concentration could undermine the potential for e-cigarettes to substitute for cigarettes and diminish the benefits of a nicotine-limiting standard for cigarettes among dual users. This study is a 12-week double-blind 2 cigarette level (Normal Nicotine vs Very Low Nicotine) x 2 e-cigarette level (High Nicotine vs Low Nicotine) between-subjects factorial trial to investigate how a nicotine-limiting standard for cigarettes affects adult dual users and whether these effects are impacted by constraints on e-cigarette nicotine concentration. Outcome measures include cigarettes per day, cigarette dependence, and toxicant exposure. The research is highly relevant to FDA CTP domains of Addiction and Behavior because it will test whether reducing the nicotine content of cigarettes reduces smoking and dependence, and whether these effects are moderated by the availability of high vs low nicotine e-cigarettes.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 4
- Model description
- 2x2 factorial randomized controlled trial
| Arm | Type | Receives |
|---|---|---|
| RC 1 + REC 1 | Experimental | Other: Varying the nicotine content of cigarettes, Other: Varying the nicotine content of e-cigarettesResearch cigarettes #1 plus research e-cigarettes #1 |
| RC 1 + REC 2 | Experimental | Other: Varying the nicotine content of cigarettes, Other: Varying the nicotine content of e-cigarettesResearch cigarettes #1 plus research e-cigarettes #2 |
| RC 2 + REC 1 | Experimental | Other: Varying the nicotine content of cigarettes, Other: Varying the nicotine content of e-cigarettesResearch cigarettes #2 plus research cigarettes #1 |
| RC 2 + REC 2 | Experimental | Other: Varying the nicotine content of cigarettes, Other: Varying the nicotine content of e-cigarettesResearch cigarettes #2 + research e-cigarettes #2 |
Who may qualify
- Ages
- 21 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Regular use of tobacco
- 21 year of age or older
- Speak, comprehend and read English well enough to complete study procedures
Key exclusion criteria (3 listed)
- Pregnant, trying to become pregnant, or nursing
- Under the age of 21
- Health conditions that could undermine ability to complete the study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Varying the nicotine content of cigarettesAlso: Comparing normal nicotine content (RC 1) to very low nicotine content (RC 2)Altering the nicotine content of the tobacco research cigarettes | Other | RC 1 + REC 1, RC 1 + REC 2, RC 2 + REC 1, RC 2 + REC 2 |
| Varying the nicotine content of e-cigarettesAlso: Comparing high nicotine content (REC 1) to low nicotine content (REC 2)Altering the nicotine content of the research e-cigarettes | Other | RC 1 + REC 1, RC 1 + REC 2, RC 2 + REC 1, RC 2 + REC 2 |
Primary outcome
Number of cigarettes smoked per day
Time frame: 12 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Jun 2025.
- Individual participant dataSharing planned: Yes. Data will be made available once we have published the results of the parent trials and manuscripts based on secondary analyses of those data, which we anticipate taking approximately three years.
Related trials for Tobacco Use Disorder
Active, not recruiting
Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS
COPD, Smoking
Recruiting
Effectiveness of Volitional Help Sheets as an Adjunct to Treatment to Promote Behavior Change: A Pilot Study on Smoking
Tobacco Dependence
Not yet recruitingEarly Phase 1
Lung Health and Breath Biomarkers: Acute Effects of Inhaled Cannabis
Cannabis Use, Tobacco
Recruiting
Young Adult Tobacco/Nicotine and Cannabis Co-use
Tobacco Use Disorder, Nicotine Dependence
RecruitingObservational study
Salivary IL-8 and Serum IL-6 as Biomarkers for Oral Potentially Malignant Disorders in Smokers and Never-Smokers
Oral Potentially Malignant Disorders, Oral Lichen Planus
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Elias Klemperer, PhD principal investigator
University of Vermont
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Varying the nicotine content of cigarettes and Varying the nicotine content of e-cigarettes in people with Tobacco Use Disorder, run by University of Vermont at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 27 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Emily Booth (802-656-1641, emily.booth@med.uvm.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of cigarettes smoked per day (time frame: 12 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Jun 2025.